Sign in
CompletedPhase 3

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Key facts

Who runs it
Arrowhead Pharmaceuticals
Where
Austin, Boca Raton, Elkridge, Indianapolis, New York, Norfolk, St Louis, and Suwanee, United StatesSee the 9 sitesAlso in 20 other countries, 48 sites
Status
Completed
Phase
Phase 3
People taking part
75 people enrolled
Started
14 Dec 2021
Ended
21 Apr 2026
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Plozasiran
  • Placebo
Record updated
5 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Fasting triglycerides (TG) ≥ 10 mmol/L (≥ 880 mg/dL) at screening refractory to standard lipid lowering therapy
  • Diagnosis of FCS
  • Willing to follow dietary counseling as per investigator judgement based on local standard of care
  • Participants of childbearing potential (males \& females) must use highly-effective contraception during the study and for at least 24 weeks following the last dose of study medication. Males must not donate sperm during the study and for at least 24 weeks following the last dose of study medication
  • Women of childbearing potential must have a negative pregnancy test at Screening and cannot be breastfeeding
  • Women of childbearing potential on hormonal contraceptives must be stable on the medication for ≥ 2 menstrual cycles prior to Day 1

Who cannot take part

  • Active pancreatitis within 12 weeks before Day 1
  • On treatment with human immunodeficiency virus (HIV) antiretroviral therapy
  • History of acute coronary syndrome event within 24 weeks of Day 1
  • History of major surgery within 12 weeks of Day 1
  • Uncontrolled hypertension
  • Seropositive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • New York Heart Association (NYHA) Clas II, III, or IV heart failure; Note: Additional Inclusion/Exclusion criteria may apply per protocol
  • Diabetes mellitus newly diagnosed within 12 weeks of Screening or where HbA1c ≥ 9.0% at Screening
  • Current use or use within the last 365 Days from Day 1 of any hepatocyte-targeted siRNA or antisense oligonucleotide molecule

Where in United States

Also in 20 other countries, 48 sites

  • Austin, TexasHospital not named in the registry
  • Boca Raton, FloridaHospital not named in the registry
  • Elkridge, MarylandHospital not named in the registry
  • Indianapolis, IndianaHospital not named in the registry
  • New YorkHospital not named in the registry
  • New YorkHospital not named in the registry
  • Norfolk, VirginiaHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry
  • Suwanee, GeorgiaHospital not named in the registry

About the trial

What the trial wants to find out

The purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching placebo administered subcutaneously. Participants who complete the randomized period will continue in a 2-year open-label extension period where all participants will receive plozasiran.

The 4 groups in the trial

  • ARO-APOC3 (Plozasiran) 25 mgTreatment being tested

    Randomized Period: plozasiran 25 mg Q3M for a total of 4 doses. Open-label Period (Parts A and B): plozasiran 25 mg Q3M for a total of 8 doses.

    Treatment: Plozasiran

  • Placebo for ARO-APOC3 (Plozasiran) 25 mgPlacebo, for comparison

    Randomized Period: volume-matched placebo every 3 months (Q3M) for a total of 4 doses. Open-label Period (Parts A and B): plozasiran 25 mg Q3M for a total of 8 doses.

    Treatment: Plozasiran and Placebo

  • ARO-APOC3 (Plozasiran) 50 mgTreatment being tested

    Randomized Period: plozasiran 25 mg Q3M for a total of 4 doses. Open-label Period: plozasiran 50 mg (Part A), then 25 mg (Part B) Q3M for a total of 8 doses.

    Treatment: Plozasiran

  • Placebo for ARO-APOC3 (Plozasiran) 50 mgPlacebo, for comparison

    Randomized Period: volume-matched placebo every 3 months (Q3M) for a total of 4 doses. Open-label Period: plozasiran 50 mg (Part A), then 25 mg (Part B) Q3M for a total of 8 doses.

    Treatment: Plozasiran and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome
Publications
Record updated
5 June 2026